Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov;10(Suppl 33):S4113-S4116.
doi: 10.21037/jtd.2018.10.53.

A leopard can't change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?

Kai Obayashi  1 , Kimihiro Shimizu  1 , Seshiru Nakazawa  1 , Yoichi Ohtaki  1 , Natsuko Kawatani  1 , Ibe Takashi  1 , Toshiki Yajima  1 , Akira Mogi  1 , Ken Shirabe  1
Affiliations
Editorial

A leopard can't change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?

Kai Obayashi et al. J Thorac Dis. 2018 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
CT image before surgery and of pulmonary metastasis with T790M mutation. A 65-year-old woman underwent a left upper lobectomy with lymph node dissection for a pulmonary adenocarcinoma (pT1bN2M0). Two years after surgery, EGFR-TKI therapy was performed for multiple pulmonary metastases. Eighteen months after treatment, T790M mutation was detected by re-biopsy in a regrowing pulmonary nodule. She underwent a third-generation EGFR-TKI therapy. (A) Axial CT image before surgery in lung window setting shows a 3.6-cm irregular lobulated mass in the left upper lobe with a peripheral location and a pleural tag (black arrowhead), vascular convergence (white arrow head); (B) an internal air bronchogram (black arrowhead); (C) CT image of pulmonary metastasis for which re-biopsy was performed. The lesion has a peripheral location and a pleural tag (black arrowhead), vascular convergence (white arrow head); (D) an internal air bronchogram (black arrowhead). CT, computed tomography; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
See this image and copyright information in PMC

Comment on

References

    1. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67. 10.1056/NEJMoa0904554 - DOI - PubMed
    1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8. 10.1056/NEJMoa0909530 - DOI - PubMed
    1. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. 10.1056/NEJMoa044238 - DOI - PubMed
    1. Uramoto H, Uchiumi T, Izumi H, et al. A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR. Anticancer Res 2007;27:2297-303. - PubMed
    1. Costa DB, Schumer ST, Tenen DG, et al. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008;26:1182-4; author reply 1184-6. 10.1200/JCO.2007.14.9039 - DOI - PubMed